Form 4: Protagonist Therapeutics Director William D. Waddill Sells 4,000 Shares

Director William D. Waddill of Protagonist Therapeutics sold 4,000 shares of common stock at a price of $54.25 per share on March 17, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 17, 2025, William D. Waddill, a director of Protagonist Therapeutics, Inc., sold 4,000 shares of the company's common stock.
• The sale was executed at a price of $54.25 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on November 10, 2023.
• Following the transaction, Waddill directly owns 13,130 shares of Protagonist Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Sales by company directors are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of acting on non-public information.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, William D. Waddill, Director, Stock Sale, Form 4, Rule 10b5-1, Insider Trading